Advances in the development of siRNA-based therapeutics for cancer

Area of Science:

• Biotechnology
• Nanomedicine
• Oncology

Background:

• Short interfering (si)RNA (siRNA) is a novel therapeutic for cancer treatment.
• Efficient delivery of siRNA to tumors is a significant obstacle in developing siRNA-based cancer therapeutics.
• Recent advancements have led to the emergence of promising siRNA delivery platforms.

Purpose of the Study:

• To review and evaluate various emerging siRNA delivery platforms for cancer therapy.
• To identify promising strategies for overcoming delivery hurdles in siRNA-based cancer therapeutics.

Main Methods:

• Review of current siRNA delivery platforms including liposomes, polyplexes, liposome-polycation-DNA (LPD) complexes, and siRNA conjugates.
• Discussion of mechanisms such as encapsulation, nanoparticle formation, and receptor-mediated endocytosis.
• Emphasis on the need for unbiased evaluation of delivery approaches.

Main Results:

• Several promising siRNA delivery platforms have emerged, including liposomes, polyplexes, LPD complexes, and siRNA conjugates.
• These platforms utilize different mechanisms for siRNA encapsulation and cellular uptake.
• The development of effective tumor delivery systems is crucial for therapeutic success.

Conclusions:

• Advancements in siRNA delivery platforms offer new hope for effective cancer treatment.
• Further unbiased evaluation is critical to select the most promising platforms for clinical development.
• Overcoming delivery challenges is key to realizing the full therapeutic potential of siRNA in oncology.